197708-07-9

Upstream product

• 197708-06-8 methyl-6-{2-[2-(ethoxycarbonyl)-(E)-ethenyl]-3-methoxyphenyl}hexanoate 
• 37418-88-5 3-hydroxyphthalic anhydride 
• 197708-04-6 methyl-6-[2-(hydroxymethyl)-3-methoxyphenyl]hexanoate 
• 197708-05-7 6-(2-Formyl-3-methoxy-phenyl)-hexanoic acid methyl ester 
• 134577-97-2 methyl 6-[2-(hydroxymethyl)-3-methoxyphenyl]-(5E)-hexenoate 

Downstream Products

• 197708-08-0 6-[2-(2-Carboxy-ethyl)-3-hydroxy-phenyl]-hexanoic acid 
• 134577-98-3 Ethyl 6-[2-(2-ethoxycarbonylethyl)-3-hydroxyphenyl]hexanoate 
• 197708-10-4 ethyl-6-{2-[2-(ethoxycarbonyl)ethyl]-3-[6-(4-methoxyphenyl)-(5E)-hexenyloxy]phenyl}hexanoate 

Relevant academic research and scientific papers

Trisubstituted benzene leukotriene B4 receptor antagonists: Synthesis and structure-activity relationships

A series of trisubstituted benzenes which demonstrate leukotriene B4 (LTB4, 1) receptor affinity was prepared. Previous trisubstituted benzenes from our laboratory showed high affinity to the LTB4 receptor but demonstrated

Phenylalkan(en)oic acid

The phenylalkan(en)oic acids of the formula: STR1 wherein A is i) --NHCO--, ii) --O-- iii) --NHSO2 --, iv) --CO-- v) --CH2 -- or vi) --CH(OH)--; W is i) C1-13 alkylene, ii) phenylene or iii) STR2 R1 is i) hydrogen, ii) C1-4 alkyl, iii) --COOH, iv) saturated or unsaturated, 4-7 membered mono-cyclic hetero ring containing one nitrogen as a hetero atom or saturated or unsaturated, 4-7 member mono-cyclic hetero ring containing one nitrogen as a hetero atom substituted by an oxo group, v) STR3 vi) --CH2 OH; or A, taken together with W and R1, is i) STR4 ii) STR5 iii) --N--(SO2 R6)2, iv) STR6 or v) STR7 two R2 are, same or different, i) hydrogen, ii) C1-4 alkyl or iii) 4-7 membered saturated or unsaturated, mono-cyclic hetero ring containing two or three of nitrogen and sulfur in total, or two R2, taken together with a nitrogen to which they are attached, form saturated or unsaturated, i) 7-14 membered, bi- or tri-cyclic hetero ring containing one nitrogen as a hetero atom, or ii) 4-7 mebered, mono-cyclic hetero ring containing two or three of nitrogen and oxygen in total; Y is ethylene or vinylene; D is i) --Z--B or ii) STR8 Z is C3-11 alkylene or alkenylene R is STR9 or Z taken together with B, is C3-22 alkyl; R3 is i) hydrogen, ii) halogen, iii) C1-8 alkyl, alkoxy or alkylthio, or iv) C2-8 alkenyl, alkenyloxy or alkenylthio; n is 1-3; R4 is C1-7 alkylene; R5 is i) C1-12 alkyl, ii) C2-12 alkenyl, iii) C5-7 cycloalkyl or pp2 iv) phenethyl or phenethyl wherein the ring is substituted by one C1-4 alkoxy; Two R6 are, same or different, i) C1-7 alkyl, ii) benzyl or iii) phenyl or phenyl wherein the ring is substituted by one C1-4 alkyl; and Two R7 are, same or different, C1-4 alky; with the proviso that i) --A--W--R1 should bind to 3- or 4- carbon in benzene ring, and ii) when W phenylene or STR10 A should not represent --O--, --CO--, --CH2 -- or --CH(OH)--; and non-toxic salts thereof, possess an antagonistic activity on leukotriene B4, and therefore, are useful for the prevention and treatment of several diseases induced by leukotriene B4.